Innovation Pharmaceuticals Inc (IPIX)

[nerby]

But in the meantime we and Ipix know lots more about Brilacidin and have begun building data and value for indications potentially much more lucrative than antibiotics. If Ipix had gone ahead with P3 for B's antibiotic action, I don't think we'd be anywhere close to where we are today on the anti-inflammatory side. And Prurisol's P2b may still be in the planning stage. I'm happy with the ways things have played out. Way I see it, Ipix traded the easy fast dollar for bigger, harder dollars. It's been hard to watch from the sidelines, for sure.